Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms

Overview

Identification of genes involved in congenital atrioventricular block and progressive Cardiac Conduction Disease.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2021

Detailed Description

Atrioventricular blocks are a heterogenous group of diseases involving children with congenital atrioventricular block (CAB) and more frequently elderly patients affected by progressive Cardiac Conduction Disease (PCCD). The aim of the study is to uncover the genetic model, likely more complex than previously appreciated, and characterize the gene expression remodelling leading to high degree of conduction defect. The recent technological developments in genomics coupled to the availability of large and highly characterized biobanks of patients have now set the stage: 1. To identify rare genetic variants/new genes contributing to CAB and PCCD by exome sequencing on familial form suspected to impact strongly the phenotype 2. To identify common genetic variants modulating the risk of developing (severe) PCCD by GWAS 3. To estimate the prevalence and relevance of genes uncovered by TASK#1, #2 in large patient sets (PCCD and CAB) by NGS.

Interventions

  • Genetic: genetic blood analysis
    • patients will undergo a blood sample (15 ml) to analyse their genetic profile

Arms, Groups and Cohorts

  • Patients with congenital atrioventricular block
    • Patient with congenital atrioventricular block
  • relatives with congenital atrioventricular block
    • Normal relatives of patients with congenital atrioventricular block
  • Patients with progressive Cardiac Conduction Disease
    • Patients with progressive Cardiac Conduction Disease,
  • relatives with progressive Cardiac Conduction disesae
    • Normal relatives of patients with progressive Cardiac Conduction Disease

Clinical Trial Outcome Measures

Primary Measures

  • Identification of genetic variations responsible of Atrioventricular Conduction Defects
    • Time Frame: inclusion

Participating in This Clinical Trial

Congenital atrioventricular block inclusion criteria:

  • Patients with idiopathic congenital atrioventricular block diagnosed before the age of 15 years. – Non-immune congenital atrioventricular block documented by a maternal serology (negative for anti-nuclear antibodies or anti Ro-SSA antibodies and anti La-SSB antibodies) – Written consent to participate to the study and written consent of both parents. – Parents of children with idiopathic congenital atrioventricular block. Congenital atrioventricular block exclusion criteria – Positive maternal serology – Patients or parents who are unable to sign or who refuse to sign an informed consent Progressive Cardiac Conduction Disease inclusion criteria – Patients with isolated cardiac conduction disorder with a normal morphology of the heart confirmed by echocardiography. – Relatives of patients with isolated cardiac conduction disorder – Written consent to participate to the study Progressive Cardiac Conduction Disease exclusion criteria – Patients with cardiac conduction disorder associated with a structural cardiopathy or due to an identified cause – Patients who are unable to sign or who refuse to sign an informed consent

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Nantes University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • vincent PROBST, MD-PHD, Principal Investigator, Nantes University Hospital
  • Overall Contact(s)
    • vincent PROBST, MD-PHD, vincent.probst@chu-nantes.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.